Introduction
Inflammatory bowel disease [IBD] , with the two main subtypes Crohn`s disease [CD] and ulcerative colitis [UC] , is a chronic inflammatory disorder of the gastrointestinal tract. The aetiopathogenesis of IBD is incompletely understood, although it is considered a multifactorial disease which arises from a complex interplay between genetic, environmental, and immunological factors, with an abnormal host immune response to environmental stimuli. 1 Different cytokines and cell interaction proteins have been identified as key players in IBD pathogenesis, such as the TNFα-NFκB axis, the JAK-STAT pathway, and the integrin-vascular adhesion molecule interaction. Several already approved drugs or investigational agents take advantage of these pathomechanisms. Anti-TNF agents have been successfully used for more than a decade, whereas anti-integrins such as vedolizumab have been introduced into clinical practice only recently. 2, 3 The latter target the gut-specific interaction between integrin α4β7 on leukocytes and the adhesion molecule MAdCAM1 on endothelial cells in the intestine, thereby blocking leukocyte adhesion and migration to the site of inflammation. Few, if any, systemic side effects are observed. 2, 3 Tofacitinib represents a first-class oral agent inhibiting the janus kinase [JAK] family of proteins, which are important mediators in inflammation. Blocking JAK downregulates proinflammatory cytokines, such as interleukin [IL] 2, 4, 7, 9, 15, and 21, through the JAK-STAT pathway. 4 Efficacy has been reported for UC but not for CD, but more specific JAK inhibitors such as filgotinib may also be efficacious in the latter indication. [5] [6] [7] Approval process for tofacitinib`s use in UC patients has been recently initiated by the US Food and Drug Administration [FDA] .
Extraintestinal manifestations [EIM] of IBD are common, with a frequency ranging from 6% to 47%. [8] [9] [10] [11] [12] [13] [14] [15] Besides arthritis and stomatitis, cutaneous manifestations are among the most prevalent EIM. 15 IBD skin lesions mainly include erythema nodosum [EN] and pyoderma gangrenosum [PG] . Whereas EN usually parallels intestinal disease activity, PG may or may not be associated with intestinal disease. The pathomechanisms of EN and PG remain elusive, although efficacy of anti-TNF treatment suggests TNFdependent mechanisms. Limited data from immunohistochemical evaluations and protein analyses from tissue lysates have demonstrated upregulation of several inflammatory cytokines, such as IL 8, 17, and 1β and TNFα in PG. 16, 17 Evidence for the efficacy of anti-TNF in EIM management is evolving. Recently, a thorough metaanalysis conducted by Peyrin-Biroulet and colleagues has shown response rates between 69% and 100% for PG and reduction of EN prevalence from 2.4% to 0.4%, with anti-TNF treatment. 18, 19 Whether other biologic agents are efficacious in the treatment of EN or PG has yet to be determined. Studies evaluating the role of vedolizumab are under way. It is yet unclear if the gut-selective mode of action limits its efficacy to the intestine or if indirect beneficial effects via decrease of intestinal inflammatory load might be relevant. No data are available so far regarding the influence of JAK inhibitors on EIM, although tofacitinib`s efficacy has been shown for other auto-inflammatory disorders such as rheumatoid arthritis and psoriasis. 20, 21 We herein investigated different proteins involved in intestinal and extraintestinal IBD manifestations, aiming at elucidating similarities and differences in IBD, cutaneous EIM, and psoriasis pathophysiology, with a special focus on possible therapeutic implications such as involvement of the TNFα-NFκB and JAK-STAT pathway as well as the integrin-MAdCAM interaction.
Methods

Study design
In this observational single-centre study, we prospectively collected intestinal and cutaneous tissue samples from healthy individuals and patients with IBD, cutaneous EIM, and psoriasis. Sample collection was conducted between 2004 and 2011. All patients had previously given their written informed consent for tissue collection and review of patient charts. All data were anonymised. The study was supported by the Swiss National Science Foundation and was approved by the local ethics committee of the University Hospital Zurich [KEK-ZH-837].
Patient and data collection
All patients analysed in this study were treated for IBD and/or inflammatory skin disease such as EN, PG, or psoriasis, at the University Hospital Zurich, Switzerland. Diagnosis of UC and CD had been previously established according to the current ECCO guidelines. 22, 23 Inflammatory skin lesions had all been diagnosed by a dermatologist. Intestinal samples from healthy controls were collected at regular screening colonoscopies at the University Hospital Zurich. Patients had to be older than 18. Endoscopic disease activity was assessed using the Mayo Clinic endoscopy subscore for UC and the CD endoscopic index of severity [CDEIS] for CD. [24] [25] [26] A score of ≥ 
Tissue sample collection
For intestinal samples, biopsies were taken from the terminal ileum [TI], caecum, and colon using a needle forceps. For skin samples, biopsies were taken from the affected lesion using a 4-6 mm surgical punch that collected epidermis, dermis and the upper subcutis. For healthy control skin, fresh, non-affected, and non-inflamed skin of unrelated surgical excisions was used. Biopsies were formalin-fixed, paraffin embedded and stored at -80°C for further use.
Tissue microarray and immunostaining
Tissue microarrays [TMA] were constructed using formalinfixed paraffin-embedded tissue blocks, which had been punched out from ileal, caecal, colonic, sigmoid, or skin tissue by a tissue cylinder [0.6 mm in diameter], as previously described. 28, 29 Immunohistochemical staining was performed using the automated system BOND RX . Categorical data are depicted as percentage of the group total. For comparisons between continuous variables, twosample t test and Mann-Whitney U test were used depending on whether data were normally distributed or not. A two-sided p-value of < 0.05 was regarded as statistically significant.
Statistical analysis
Results
Tissue samples
A total of 304 intestinal and skin tissue samples were collected; 240 intestinal biopsies were taken from a total of 106 patients. These samples showed active endoscopic IBD in 108 cases and endoscopic inactivity in 77 cases; 55 intestinal biopsies were taken from 29 healthy controls; 64 skin samples were collected from 64 patients: 53 patients had an inflammatory skin disorder [ 
Patient demographics
Of the samples, 156 [51.3%] were taken from male patients, whose mean age was 43.7 years [SD 9.7] . Patients with PG were significantly older, and there were significantly less males in the EN group. The other groups were comparable regarding gender and age. Of the 185 IBD intestinal samples, 36 showed endoscopically active CD, 26 non-active CD, 72 endoscopically active UC, and 51 non-active UC. Of the 72 samples with endoscopic UC activity, 31 were collected from patients with pancolitis and 41 from patients with leftsided UC. All of the 36 samples with active CD were taken from ileal [n = 19] or caecal [n = 17] disease, and the samples for inactive CD were collected from non-inflamed TI [n = 13] or non-affected caecum [n = 13]. Two IBD patients reported a previous anti-TNF treatment which was, however, stopped more than 8 weeks before biopsy. At the time of skin biopsy, none of the patients with skin disorders were treated with systemic or topical anti-inflammatory drugs. None of them had a history of a previous use of biologic treatment. None of the patients with psoriasis had underlying IBD. Table 1 
Expression of MAdCAM1
Expression of other proteins
We assessed the expression of several other proteins involved in inflammatory processes and cell injury. Caspase 3 upregulation significantly distinguished PG and EN from healthy controls and psoriasis: caspase 3 was higher in both EN [20. 
Discussion
This single-centre observational study, with assessment of protein expression patterns in IBD, cutaneous EIM, and psoriasis compared with healthy controls, shows similar upregulation of TNFα and STAT3 in both intestinal and cutaneous disease, but absence of MAdCAM1 overexpression in inflammatory skin disorders. TNFα and STAT3 are both considerably upregulated in EN and PG, with even higher expression levels compared with psoriasis. Protein expression patterns of EN and PG show many similarities, with only few differences revealing important therapeutic implications. The TNFα-NFκB axis is overexpressed in both intestinal disease and inflammatory skin disorders, with an even more pronounced upregulation in PG and EN compared with psoriasis. TNFα was recognised as an important inflammatory parameter in different autoimmune diseases, including IBD and psoriasis, many years ago. Anti-TNF agents take advantage of this canonical inflammatory pathway. They have been successfully introduced in the past decade and have changed IBD management dramatically. Their potential beneficial role in EIM management had been first proposed based on small case series and case reports. 31 Very recently, Peyrin-Biroulet and colleagues nicely summarised their efficacy in a meta-analysis demonstrating high response rates for PG [69-100%] and EN [prevalence reduction from 2.4% to 0.4%]. Complete remission rates for PG were however lower [25-100%] . 18, 19 PG actually is the only cutaneous IBD manifestation where a randomised controlled trial is available for showing clinical improvement in 69% and a complete remission in 25% of the patients after an induction treatment with infliximab. 32 Further data from the Swiss IBD cohort study support these data, demonstrating improvement rates of 60% for PG and 80% for EN. 33 This has led to the current understanding of a TNFdependent pathogenesis in cutaneous EIM. In PG samples, TNFα upregulation has been reported previously, but no such data are available for EN. Our data showing overexpression in both PG and EN, even higher levels when compared with psoriasis, are compatible with the known efficacy of anti-TNF efficacy in cutaneous EIM. 16 Although the TNFα-NFκB axis was upregulated in both CD and UC with a particular overexpression of intracellular NFκB, TNFα was actually only significantly increased in intestinal samples from active CD, but not from UC. There are three possible explanations: 1] the finding that TNFα levels in the lamina propria are indeed higher in CD than UC has been already described more than two decades ago; 34 2] for detection of the small difference between healthy controls and UC, our study was probably underpowered; and 3] other factors such as bacterial products [e.g. lipopolysaccharides, LPS] can lead to NFκB upregulation independent of TNFα, so [over]expression of the two proteins do not necessarily go in parallel.
The anti-integrin vedolizumab has been introduced into clinical practice very recently. Data from randomised controlled trials demonstrated vedolizumab`s efficacy in both CD and UC. 2, 3 Vedolizumab`s role in EIM management has not yet been defined. Its gut-selective mechanism advocates against, whereas some preliminary data presented at recent congresses advocate for, an at least partial efficacy in the treatment of EIM. 35 Consistently with the literature, we herein report on isolated MAdCAM1 expression in the inflamed intestine, but not in inflammatory skin disorders, which makes a direct effect on cutaneous EIM extremely unlikely. However, vedolizumab might have a role in EIM management by treating intestinal disease activity in EIM that parallels IBD.
The third biologic, which is currently being reviewed by the US FDA for treatment in UC patients, is the JAK inhibitor tofacitinib, which has been successfully used in other diseases such as rheumatoid arthritis and psoriasis. 20, 21 Tofacitinib inhibits the JAK-STAT pathway which incites pro-inflammatory signals. Biopsies from active intestinal disease and inflammatory skin disorders demonstrated similar results regarding STAT3 overexpression in our patient cohort. Difference between healthy controls and inflamed tissue was even more prominent in skin biopsies. Of note, STAT3 was significantly more upregulated in PG/EN than in psoriasis, shedding light on the potential benefit from JAK inhibition in those patients. Clinical data are not available so far, but our findings make a therapeutic response to JAK inhibitors very likely. Given tofacitinib`s current blackbox warning for serious infections, possible systemic side effects from pan-JAK inhibitors should be kept in mind; these, however, occur less frequently with more specific JAK inhibitors such as filgotinib.
With the microarray approach, several other interesting targets for EIM management have been identified by screening markers for B lymphocytes [CD20], macrophages [CD68], apoptosis [caspase 3 and 9], and inflammation-induced anti-apoptotic factors [Hsp-27/70]. Both caspase 3 and CD68 were overexpressed in EN and PG compared with healthy controls and psoriasis, highlighting the overlap between cutaneous EIM with a protein expression profile distinct from that of other inflammatory skin diseases. Anti-caspases are currently tested in liver diseases [emricasan in non-alcoholic steatohepatitis, NCT02686762], but no data are available so far for EIM or IBD.
Our study has several strengths, but also some limitations. To the best of our knowledge, it is so far the only study investigating protein expression patterns in IBD and cutaneous EIM in IBD and comparing them with healthy controls and psoriasis. Microarray is a widely used and reliable tool to study expression of various proteins. Variation due to TMA technology has been limited using only duplicate samples. None of the patients with inflammatory skin disorders was treated with either topical or systemic anti-inflammatory drugs, which makes the TMA results more reliable. In addition, previous anti-TNF treatment was reported in two IBD patients only, and treatment was stopped more than 8 weeks before study evaluation, making interference with biopsy results less likely. All TMA were analysed by experts in TMA evaluation, and involvement of only two pathologists has limited inter-observer variability. We were able to include 13 patients with PG despite its rarity [prevalence 2% of Swiss IBD population, incidence 0.63/100 000] due to the close collaboration with our department of dermatology and a study enrolment over several years. 15, 36 A limitation of the TMA technology is that tissue sample heterogeneity is not completely taken into account. The study was cross-sectional without any followup, and therefore changes in expression levels in response to any biologic treatment could not be assessed. The study relied on protein expression levels only, and did not include analysis of mRNA levels. A further drawback of this study is that we only identified MAdCAM1 overexpression in active UC, not in active CD samples. This might be due to: 1] the low number of samples from active CD [n = 36] compared with the relatively high number of active UC [n = 72]; and 2] the inclusion of non-severe CD cases given the very low cut-off of CDEIS ≥ 3. 37 Whereas upregulation of TNFα in cutaneous EIM compared with healthy controls is compatible with the known efficacy of anti-TNF in EIM management, the lack of MAdCAM1 overexpression in the human skin, even in the context of inflammation, questions the role of vedolizumab in EIM treatment. Its only effect might be indirect, through inducing and maintaining intestinal disease remission in those EIM parallelling IBD activity. Data on upregulated STAT give a rationale for JAK inhibitors in both EN and PG management, particularly in the current context of missing clinical studies. Data from randomised controlled trials evaluating the effect of anti-integrins and JAK inhibitors on EIM are, however, urgently needed.
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